

REMARKS

Upon entry of the above amendment, 1-14 and 16 will be pending in the present application. Claim 15 has been canceled without prejudice. Claim 1 is independent. Applicants have amended the claims to conform to U.S. Patent practice. The specification on pages 21 and 22 provide support for new claim 16. Applicants have not added any new matter.

Conclusion


Applicants submit that the present claims define patentable subject matter and are in condition for allowance.

Should the Examiner believe that a conference would be helpful in advancing the prosecution of this application, he is invited to telephone Applicants' Attorney at the number below. If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334 for any additional

Attorney Docket No.: O 2002.724 US  
U.S.P.T.O. Customer Number: 31846

fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly,  
extension of time fees.

Respectfully submitted,

  
\_\_\_\_\_  
Mark W. Milstead  
Attorney for Applicants  
Registration No. 45,825

Akzo Nobel Pharma Patent Dept.  
P.O. Box 318  
29160 Intervet Lane  
Millsboro, DE 19966  
Tel: (302) 933-4034  
Fax: (302) 934-4305

Enclosure: Abstract of the Disclosure